The CDC preferentially recommends individuals receive mRNA vaccines

Tuesday Dec 21st, 2021

The CDC preferentially recommends individuals receive mRNA vaccines - Moderna or Pfizer - for the prevention of COVID-19 over the Johnson & Johnson vaccine. This recommendation follows similar recommendations from other countries such as Canada and the United Kingdom. The decision to preferentially recommend mRNA vaccines was based on evolving evidence on vaccine safety, effectiveness, and adverse events. 

The Baltimore City Health Department recommends that all eligible residents receive the mRNA vaccine - Moderna or Pfizer - for their primary series (first two doses) and their booster. If an individual 18 years and older is unable to receive a mRNA vaccine due to a history of allergic reactions, anaphylaxis, or other contraindication a Johnson & Johnson booster may be given. 

The CDC Endorses ACIP’s Updated COVID-19 Vaccine Recommendations https://www.cdc.gov/media/releases/2021/s1216-covid-19-vaccines.html

See more COVID-19 updates

Related Stories

Baltimore City Health Department Selects Community Covid-19 Test Kit Distribution Sites

BALTIMORE, MD. (April 14, 2022) – The Baltimore City Health Department (BCHD) is excited to announce additional COVID-19 Test Kit Distribution partners. Residents can find a list of COVID-19 Test Kit Distribution partners on the Health Department’s website. Organizations will receive a supply of COVID-19 at-home test kits for distribution to the community and will advertise distribution plans. Organizations were selected via an application process that considered representation across BCHD’s COVID-19 VALUES communities and geographic coverage across the city. 

Information about COVID-19 booster doses

Booster doses are currently authorized by the FDA and recommended by CDC for all individuals 12 years and older.

Additional doses for people 5 years and older with moderate to severe immune compromise

The Baltimore City Health Department recommends that people 5 years and older who are moderately to severely immunocompromised rec

Visit the Newsroom